Kunming

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Hepatitis B3 trials
• Colorectal cancer2 trials
• Asthma1 trial
• COPD1 trial
• Head and neck cancer1 trial

Phase

• Phase 36 trials
• Phase 22 trials

Status

• Completed3 trials
• Recruiting3 trials
• Active, not recruiting2 trials

Lead sponsor

• GlaxoSmithKline8 trials

Running trials

• Recruiting

  Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation

  NCT06959095· Phase 3· GlaxoSmithKline· Source

  Contact: Zhuang Luo (principal investigator)

• Active, not recruiting

  A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China

  NCT06640049· Phase 2· GlaxoSmithKline· Source

• Recruiting

  A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

  NCT06256588· Phase 3· GlaxoSmithKline· Source

  Contact: Chuanzheng Sun (principal investigator)

• Recruiting

  Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

  NCT05855200· Phase 3· GlaxoSmithKline· Source

  Contact: Jian Dong (principal investigator)

• Active, not recruiting

  Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)

  NCT04954859· Phase 2· GlaxoSmithKline· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer1 recruiting
• COPD1 recruiting
• Head and neck cancer1 recruiting

Closed trials

• Completed

  Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)

  NCT05630807· Phase 3· GlaxoSmithKline· Source

• Completed

  Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)

  NCT05630820· Phase 3· GlaxoSmithKline· Source

• Completed

  Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma

  NCT04937387· Phase 3· GlaxoSmithKline· Source